Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barrÉ syndrome and huntington's disease at aan 2022

Brisbane, calif., march 03, 2022 (globe newswire) -- annexon, inc. (“annexon”) (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that the company will present preclinical data highlighting its approach of inhibiting c1q to address a number of complement-mediated diseases. the data are being presented in oral and poster sessions at the american academy of neurology (aan) annual meeting, being held in seattle from april 2-7, 2022, and virtually from april 24-26, 2022.
ANNX Ratings Summary
ANNX Quant Ranking